Drug Profile
RXDX 105
Alternative Names: AC 013773; CEP-32496; RXDX-105Latest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator Ambit Biosciences Corporation; Cephalon
- Developer Ignyta
- Class Antineoplastics; Isoxazoles; Phenyl ethers; Phenylurea compounds; Quinazolines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists; Proto oncogene protein b raf inhibitors; Proto oncogene protein c ret inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (PO)
- 24 Apr 2019 Ignyta completes with an expanded access to RXDX 105 for Cancer in USA (PO) (NCT03052569)
- 01 Feb 2019 Ignyta completes a phase I/Ib trial for Solid tumours in USA (NCT01877811)